Having shown that the GSE1 and TACSTD2 interaction and expression profiles reflect abiraterone/enzalutamide drug resistance, androgen sensitivity, and castration resistance in patients with PCa, we assessed the potential effect of targeting GSE1/TACSTD2 signaling through the shRNA-mediated inhibition of GSE1 (shGSE1). This evidence concerns the gene TACSTD2 and posterior cortical atrophy.